MipTec - International Life Science Exhibition 2015
- Messe Basel.
- Date: Tuesday, September 22, 2015 – Thursday, September 24, 2015
Meet us this year at MipTec in Basel - booth #D59! Come along to discover the newest Promega solutions.
Join the talk by Dr. Mei Cong "Reporter Bioassays to Assess Therapeutic Antibodies in Development for Immunotherapy Programs
Tuesday, September 22
12:30 – 13:30
Reporter Bioassays to Assess Therapeutic Antibodies in Development for Immunotherapy Programs
Mei Cong PhD, Director of CAS, Promega R&D
Department of Research, Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Cancer immunotherapy was named the 2013 “Breakthrough of the Year” by Science, and aims to stimulate a patient’s own immune system to treat cancer. Key inhibitor drugs in the market such as anti-Programmed cell Death protein 1 PD-1 antibodies nivolumab (Opdivo), lambrolizumab (Keytruda), and ipilimumab (Yervoy, an anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) antibody) are providing long-term benefits to cancer patients. Traditional inhibitory blockade studies commonly use animal models or freshly isolated peripheral blood mononuclear cells (PBMCs) to quantify antibody drug biological activity. However, animal models can be cost-prohibitive and cell acquisition and preparation is labor intensive and the bioassays incorporating such cells have high inherent variability. Here we demonstrate multiple bioluminescent reporter-based assays that can be used to rapidly measure potencies of multiple biological immunotherapy drugs including PD-1/PD-L1, CTLA4, LAG-3, GITR and CD40. We also demonstrate that these bioassays reflect mode of action of each drug, and quantify potencies of on-market monoclonal antibody drugs for cancer.
Mei Cong is a Director at Promega Research leading a team of scientists in products and custom assay development. It includes reporter vectors, cell lines, as well as other assays and tools based on our luciferase and HaloTag™ protein fusion tag technologies, such as custom NanoBRET™ assays for PPI and target engagement. Mei has recently been focused on leading the development of reporter assays useful for measuring activities of biologic drugs in immunotherapy. Dr. Mei Cong received her Ph.D. in Biochemistry from the University of Arizona. She completed her post-doctoral training on GPCR signal transduction pathway regulation with Dr. Robert Lefkowitz, 2012 Nobel Laureate in Chemistry at Duke University Medical Center. Prior to joining Promega, Mei spent over 14 years in pharma and biotech developing and delivering robust cell-based assays.